semaglutide sustained release (PT403) / Peptron - LARVOL DELTA

Peptron seeks Korea phase 1 trial for once-monthly semaglutide obesity drug (Chosun Biz) - "The phase 1 trial will evaluate the safety, tolerability, and pharmacokinetic (PK) profile after a single subcutaneous dose of PT403 in 22 healthy adults. It will be conducted at the Chungnam National University Hospital Clinical Trial Center....The trial will systematically evaluate the safety, tolerability, and pharmacokinetic characteristics of PT403."

New P1 trial • Obesity

Peptron secures Australian patent for long-acting semaglutide injection (Korea Biomedical Review) - "Peptron...that it has secured a patent in Australia for a long-acting injectable formulation of semaglutide, designed to last over one month....The patent covers PT403, the company’s diabetes and obesity treatment candidate, which is based on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist....The patent ensures Peptron’s exclusive rights to PT403 and similar formulations in Australia until June 22, 2042."

Patent • Diabetes • Metabolic Disorders • Obesity